Replies to post #209485 on Biotech Values

[DewDiligence]

MYL +7% on 4Q16 results /2017 guidance:

http://newsroom.mylan.com/2017-03-01-Mylan-Reports-Fourth-Quarter-and-Full-Year-2016-Results-and-Provides-2017-Guidance

"We look forward in 2017 to delivering yet another strong year of performance, with anticipated 2017 revenues of $12.25 billion to $13.75 billion and adjusted [i.e. non-GAAP] EPS of $5.15 to $5.55.

We also continue to advance toward our long-stated 2018 adjusted EPS target of $6.00."

At the midpoint of the guidance ranges, 2017 revenue of $13.0B would be +17% YoY and 2017 non-GAAP EPS of $5.35 would be +9% YoY.

At the current share price, the forward P/E (based on the $5.35 of projected non-GAAP EPS) is 8.4x. If this seems low, bear in mind that MYL excludes a lot of stuff from its non-GAAP EPS numbers.